SVA
Income statement / Annual
Last year (2023), Sinovac Biotech Ltd.'s total revenue was $448.27 M,
a decrease of 69.97% from the previous year.
In 2023, Sinovac Biotech Ltd.'s net income was -$99.92 M.
See Sinovac Biotech Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$448.27 M |
$1.49 B |
$19.37 B |
$510.62 M |
$246.05 M |
$229.65 M |
$174.35 M |
$72.43 M |
$67.41 M |
$62.93 M |
| Cost of Revenue |
$181.52 M
|
$684.46 M
|
$1.07 B
|
$67.18 M
|
$32.47 M
|
$24.72 M
|
$20.24 M
|
$22.39 M
|
$18.41 M
|
$15.48 M
|
| Gross Profit |
$266.75 M
|
$808.31 M
|
$18.30 B
|
$443.44 M
|
$213.58 M
|
$204.93 M
|
$154.11 M
|
$50.04 M
|
$49.01 M
|
$47.46 M
|
| Gross Profit Ratio |
0.6
|
0.54
|
0.95
|
0.87
|
0.87
|
0.89
|
0.88
|
0.69
|
0.73
|
0.75
|
| Research and Development Expenses |
$344.52 M
|
$442.11 M
|
$155.04 M
|
$48.76 M
|
$24.25 M
|
$21.91 M
|
$20.49 M
|
$12.65 M
|
$9.49 M
|
$10.93 M
|
| General & Administrative Expenses |
$466.32 M
|
$823.54 M
|
$591.17 M
|
$176.53 M
|
$121.47 M
|
$137.00 M
|
$0.00
|
$41.98 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$466.32 M
|
$823.54 M
|
$591.17 M
|
$176.53 M
|
$121.47 M
|
$137.00 M
|
$87.37 M
|
$41.98 M
|
$37.48 M
|
$34.34 M
|
| Other Expenses |
$2.64 M
|
$301.75 M
|
-$89.95 M
|
$496,000.00
|
$912,000.00
|
$321,000.00
|
$13,000.00
|
$100,000.00
|
-$174,000.00
|
$1.19 M
|
| Operating Expenses |
$813.48 M
|
$1.27 B
|
$748.45 M
|
$227.64 M
|
$144.73 M
|
$159.54 M
|
$108.65 M
|
$49.06 M
|
$45.29 M
|
$45.50 M
|
| Cost And Expenses |
$994.99 M
|
$1.95 B
|
$1.82 B
|
$294.82 M
|
$177.20 M
|
$184.26 M
|
$128.89 M
|
$71.45 M
|
$63.69 M
|
$60.97 M
|
| Interest Income |
$85.11 M
|
$190.82 M
|
$102.57 M
|
$1.93 M
|
$2.00 M
|
$2.02 M
|
$1.18 M
|
$731,000.00
|
$1.16 M
|
$2.68 M
|
| Interest Expense |
$2.26 M
|
$1.26 M
|
$2.84 M
|
$1.45 M
|
$650,000.00
|
$1.07 M
|
$1.57 M
|
$1.73 M
|
$1.92 M
|
$3.41 M
|
| Depreciation & Amortization |
$144.75 M
|
$156.60 M
|
$100.43 M
|
$6.63 M
|
$8.02 M
|
$5.14 M
|
$4.88 M
|
$5.34 M
|
$6.52 M
|
$8.10 M
|
| EBITDA |
-$6.03 M |
$183.10 M |
$17.65 B |
$221.76 M |
$76.05 M |
$52.54 M |
$51.25 M |
$6.65 M |
$10.93 M |
$13.86 M |
| EBITDA Ratio |
-0.01
|
0.13
|
0.91
|
0.44
|
0.31
|
0.23
|
0.3
|
0.1
|
0.17
|
0.22
|
| Operating Income Ratio |
-1.22
|
-0.31
|
0.91
|
0.42
|
0.28
|
0.2
|
0.26
|
0.01
|
0.05
|
0.03
|
| Total Other Income/Expenses Net |
$393.69 M
|
$491.31 M
|
$9.78 M
|
$973,000.00
|
$2.26 M
|
$1.27 M
|
-$373,000.00
|
-$898,000.00
|
-$939,000.00
|
$463,000.00
|
| Income Before Tax |
-$153.03 M
|
$25.24 M
|
$17.56 B
|
$216.62 M
|
$70.82 M
|
$46.58 M
|
$45.04 M
|
-$394,000.00
|
$2.76 M
|
$2.35 M
|
| Income Before Tax Ratio |
-0.34
|
0.02
|
0.91
|
0.42
|
0.29
|
0.2
|
0.26
|
-0.01
|
0.04
|
0.04
|
| Income Tax Expense |
$105.32 M
|
-$62.89 M
|
$3.10 B
|
$31.44 M
|
$5.61 M
|
$10.47 M
|
$8.34 M
|
$2.66 M
|
$2.99 M
|
$2.07 M
|
| Net Income |
-$99.92 M
|
$113.87 M
|
$8.47 B
|
$110.37 M
|
$44.93 M
|
$21.78 M
|
$25.81 M
|
-$596,000.00
|
-$1.42 M
|
-$1.52 M
|
| Net Income Ratio |
-0.22
|
0.08
|
0.44
|
0.22
|
0.18
|
0.09
|
0.15
|
-0.01
|
-0.02
|
-0.02
|
| EPS |
-1.06 |
1.08 |
85.2 |
1.06 |
0.42 |
0.34 |
0.45 |
-0.0105 |
-0.0251 |
-0.0272 |
| EPS Diluted |
-1.06 |
1 |
74.27 |
0.97 |
0.41 |
0.34 |
0.45 |
-0.0105 |
-0.0251 |
-0.0272 |
| Weighted Average Shares Out |
$99.61 M
|
$99.50 M
|
$99.31 M
|
$98.90 M
|
$94.88 M
|
$64.73 M
|
$57.03 M
|
$56.95 M
|
$56.31 M
|
$55.68 M
|
| Weighted Average Shares Out Diluted |
$99.61 M
|
$114.17 M
|
$114.01 M
|
$113.66 M
|
$109.69 M
|
$64.98 M
|
$57.10 M
|
$56.95 M
|
$56.31 M
|
$55.68 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
